Volume 67, Issue 5, Pages (November 2017)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 61, Issue 2, Pages (August 2014)
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies  Gennaro D'Amico, Guadalupe Garcia-Tsao, Luigi.
Volume 61, Issue 5, Pages (November 2014)
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis  Wichit Srikureja,
Primary prevention of variceal haemorrhage: A pharmacological approach
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
NS5A inhibitors in the treatment of hepatitis C
Immigration and viral hepatitis
Volume 66, Issue 1, Pages 1-4 (January 2017)
Living donor liver transplantation: is the hype over?
Volume 42, Issue 4, Pages (April 2005)
Reply to: “DCD consensus and futility in liver transplantation”
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
Mauro Bernardi, Stefano Gitto, Maurizio Biselli  Journal of Hepatology 
Hepatitis C core protein – The “core” of immune deception?
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Burcin Ekser, Eric Lagasse  Journal of Hepatology 
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
Volume 70, Issue 1, Pages (January 2019)
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Volume 61, Issue 5, Pages (November 2014)
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 62, Issue 3, Pages (March 2015)
Volume 44, Issue 1, Pages (January 2006)
EASL Clinical Practice Guidelines: Wilson’s disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Volume 61, Issue 1, Pages S45-S57 (November 2014)
Volume 44, Issue 2, Pages (February 2006)
Stephen Locarnini, Angelos Hatzakis, Ding-Shinn Chen, Anna Lok 
Julie Parkes, Indra Neil Guha, Paul Roderick, William Rosenberg 
Wolfgang Sieghart, Florian Hucke, Markus Peck-Radosavljevic 
Volume 41, Issue 4, Pages (October 2004)
The changing role of beta-blocker therapy in patients with cirrhosis
Volume 65, Issue 2, Pages (August 2016)
Volume 57, Issue 5, Pages (November 2012)
Hepatology may have problems with putative surrogate outcome measures
Volume 50, Issue 4, Pages (April 2009)
Non-invasive diagnosis and biomarkers in alcohol-related liver disease
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Paul C. Adams, James C. Barton  Journal of Hepatology 
Volume 67, Issue 5, Pages (November 2017)
Volume 50, Issue 3, Pages (March 2009)
Immigration and viral hepatitis
Global burden of alcoholic liver diseases
HCV targeting of patients with cirrhosis
Volume 64, Issue 6, Pages (June 2016)
The impact of intestinal microflora on serum bilirubin levels
Volume 63, Issue 1, Pages (July 2015)
Familial amyloidosis: Great progress for an orphan disease
Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection  Isabelle Chemin,
Chronic hepatitis B in children and adolescents
Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice  Paolo Angeli, Pere Gines 
Volume 66, Issue 3, Pages (March 2017)
Volume 62, Issue 3, Pages (March 2015)
Volume 46, Issue 3, Pages (March 2007)
Liver transplantation in children
Pathogenesis of cholestatic hepatitis C
Volume 50, Issue 1, Pages 4-6 (January 2009)
Genetics of hepatocellular carcinoma: The next generation
Volume 70, Issue 5, Pages (May 2019)
Fondaparinux (Arixtra∗) hepatotoxicity in a 6 year-old child
Presentation transcript:

Volume 67, Issue 5, Pages 1026-1030 (November 2017) A heterozygous mutation in GOT1 is associated with familial macro-aspartate aminotransferase  Maria Kulecka, Aldona Wierzbicka, Agnieszka Paziewska, Michal Mikula, Andrzej Habior, Wojciech Janczyk, Michalina Dabrowska, Jakub Karczmarski, Michal Lazniewski, Krzysztof Ginalski, Anna Czlonkowska, Piotr Socha, Jerzy Ostrowski  Journal of Hepatology  Volume 67, Issue 5, Pages 1026-1030 (November 2017) DOI: 10.1016/j.jhep.2017.07.003 Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Prevalence of the glutamate oxaloacetate transaminase 1 (GOT1) p.Gln208Glu mutation in families with at least two occurrences of macro-aspartate aminotransferase. Journal of Hepatology 2017 67, 1026-1030DOI: (10.1016/j.jhep.2017.07.003) Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Fig. 2 The serum aspartate aminotransferase (AST) activity levels in subjects diagnosed with macro-AST who were either carriers or non-carries of glutamate oxaloacetate transaminase 1 p.Gln208Glu mutation. The statistical difference was assessed with Welch Two Sample t test. Journal of Hepatology 2017 67, 1026-1030DOI: (10.1016/j.jhep.2017.07.003) Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Location of the p.Gln208Glu mutation, identified in patients with macro-aspartate aminotransferase (AST), in the structure of the human glutamate oxaloacetate transaminase 1 homodimer. The amino acid mutated in macro-AST is shown in red. Monomers are colored blue and gray, while key residues from both active sites are indicated in yellow and magenta. (This figure appears in colour on the web.) Journal of Hepatology 2017 67, 1026-1030DOI: (10.1016/j.jhep.2017.07.003) Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2017 67, 1026-1030DOI: (10. 1016/j. jhep. 2017 Copyright © 2017 European Association for the Study of the Liver Terms and Conditions